title: Effects of methotrexate upon inflammatory parameters induced by carrageenan in the mouse model of pleurisy.
abstract: BACKGROUND
  The model of pleurisy induced by carrageenan exhibits a biphasic response (4 and 48 h) and permits the quantification of exudate, cell migration and certain enzymes such as myeloperoxidase (MPO) and adenosine-deaminase (ADA) that are markers of activated leukocytes.
  
  
  OBJECTIVE
  The present study evaluates whether there exists, in the pleurisy model, a significant inhibition of ADA and MPO enzymes, leukocyte kinetics and other markers of inflammation [nitric oxide (NO) levels, exudation] caused by methotrexate treatment by the intraperitoneal (i.p.) route.
  
  
  METHODS
  The pleurisy was induced by carrageenan (1%) in mice, and the parameters were analyzed 4 and 48 h after.
  
  
  RESULTS
  After the induction of inflammation (4 h), methotrexate (20 mg/kg, i.p., 24 h before pleurisy induction) inhibited the leukocyte infiltration (p < 0.05), NO levels and MPO activity (p < 0.01), but not ADA activity and fluid leakage (p > 0.05). Regarding the second phase of pleurisy (48 h), methotrexate (40 mg/kg, i.p., 0.5 h before pleurisy induction) inhibited the leukocyte infiltration (p < 0.05), fluid leakage, NO levels (p < 0.01), and ADA and MPO activity (p < 0.05).
  
  
  CONCLUSIONS
  These findings support the evidence that the acute administration of methotrexate has an important systemic anti-inflammatory activity in the studied inflammatory model. This effect was due to a significant inhibition on both neutrophil and mononuclear cells, being less marked in relation to exudation 48 h after. In relation to the enzymes studied and to NO levels, the findings support the evidence that methotrexate inhibits both enzymes (MPO and ADA) from leukocytes at the site of injury, thus reflecting the activation of both neutrophils and lymphocytes, respectively. Furthermore, the inhibiting effect on NO in both phases of pleurisy induced by carrageenan (4 and 48 h) indicates that methotrexate acts on constitutive and/or inducible NO synthases by means of different cells of the pleural cavity.
authors.affiliation: Department of Clinical Analysis, Center of Health Sciences, Universidade Federal de Santa Catarina, Campus Universitário-Trindade, 88040-970, Florianópolis, SC, Brazil.
authors.forename: Eduardo Monguilhott
authors.initials: EM
authors.lastname: Dalmarco
authors.forename: Tânia Silvia
authors.initials: TS
authors.lastname: Fröde
authors.forename: Yara Santos
authors.initials: YS
authors.lastname: Medeiros
mesh_terms: D000243:Adenosine Deaminase / Q000378:metabolism; D000818:Animals; D002351:Carrageenan; D004195:Disease Models, Animal; D005260:Female; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008297:Male; D008727:Methotrexate / Q000494:pharmacology*; D051379:Mice; D009569:Nitric Oxide / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism; D010994:Pleura / Q000201:enzymology / Q000276:immunology; D010998:Pleurisy / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D007166:Immunosuppressive Agents; D009569:Nitric Oxide; D002351:Carrageenan; D009195:Peroxidase; D000243:Adenosine Deaminase; D008727:Methotrexate